Last reviewed · How we verify
Methylprednisolone Injectable Suspension
Methylprednisolone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Methylprednisolone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Acute inflammatory and autoimmune disorders, Multiple sclerosis exacerbations, Severe allergic reactions.
At a glance
| Generic name | Methylprednisolone Injectable Suspension |
|---|---|
| Also known as | Methylprednisolone pulse therapy, Solumedrol |
| Sponsor | Nanjing University School of Medicine |
| Drug class | Glucocorticoid (corticosteroid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Neurology |
| Phase | Phase 3 |
Mechanism of action
Methylprednisolone exerts its anti-inflammatory and immunosuppressive effects by entering cells and binding to cytoplasmic glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and reduced immune cell activation and proliferation. The injectable suspension formulation allows for rapid systemic delivery and is commonly used for acute inflammatory and autoimmune conditions requiring high-dose corticosteroid therapy.
Approved indications
- Acute inflammatory and autoimmune disorders
- Multiple sclerosis exacerbations
- Severe allergic reactions
- Rheumatoid arthritis and other rheumatologic conditions
- Cerebral edema
Common side effects
- Hyperglycemia
- Insomnia
- Mood changes (euphoria, anxiety)
- Hypertension
- Immunosuppression / increased infection risk
- Osteoporosis (with chronic use)
- Gastrointestinal upset
Key clinical trials
- Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression (PHASE3)
- Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. (PHASE2, PHASE3)
- A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis (PHASE1)
- Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract (PHASE4)
- Methylprednisolone Injections Treating Birch Pollen Induced Allergic Rhinitis. (PHASE4)
- The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis (PHASE3)
- Comparison of Aerosol Inhalation and Intravenous Glucocorticoid in the Treatment of Severe AECOPD (NA)
- Use of Corticosteroids in Third Molar Surgery (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: